Drugs / CAR7-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04823091 | Apr 2021 → Apr 2023 | T-cell leukemia, T-cell non-Hodgkin lymphoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR7-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04823091 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor-T cells (CAR-T) have made breakthroughs” NCT04823091 ↗ |
| Target | CD7 | “CD7-directed cytotoxicity” NCT04823091 ↗ |